

# **Zydus Pharmaceuticals (USA) INC.**

## **CONSOLIDATED FINANCIAL STATEMENTS**

**March 31, 2024 and 2023**

**RAM ASSOCIATES, CPAS**

3240 East State Street Ext.  
Hamilton, NJ 08619  
Tel: 609 631 9552 / 609 631 9553  
Fax: 888 319 8898  
email: [pkram@ramassociates.us](mailto:pkram@ramassociates.us)

# ZYDUS PHARMACEUTICALS (USA) INC.

## TABLE OF CONTENTS

---

	<u>Page</u>
INDEPENDENT AUDITOR'S REPORT	1
Consolidated Financial Statements	
Consolidated Balance Sheets as of March 31, 2024 and 2023 .....	2
Consolidated Statements of Income / (Operations) For The Years Ended March 31, 2024 and 2023 .....	3
Consolidated Statements of Changes in Stockholders' Equity For The Years Ended March 31, 2024 and 2023 .....	4
Consolidated Statements of Cash Flows For The Years Ended March 31, 2024 and 2023 .....	5
Notes to Financial Statements .....	6-27

**ZYDUS PHARMACEUTICALS (USA) INC.**  
**Consolidated Balance Sheets**  
**March 31,**

*(all in thousands except shares)*

	<b>2024</b>	<b>2023</b>
<b><u>ASSETS</u></b>		
<b>Current assets :</b>		
Cash	\$ 5,610	\$ 12,118
Accounts receivable	386,924	358,951
Inventories	281,898	197,056
Prepaid expenses	3,398	3,036
Other current assets	17,977	3,929
Current assets held-for-sale	151	206
<b>Total current assets</b>	<b>695,958</b>	<b>575,296</b>
<b>Fixed assets, net</b>	7,480	6,509
<b>Intangible assets, net</b>	112	108
<b>Operating lease right-of-use asset</b>	600	1,006
<b>Deferred tax assets</b>	63,524	30,480
<b>Other assets</b>	143,696	82,850
<b>Noncurrent assets held-for-sale</b>	-	474
<b>TOTAL ASSETS</b>	<b>\$ 911,370</b>	<b>\$ 696,723</b>
<b><u>LIABILITIES AND STOCKHOLDERS' EQUITY</u></b>		
<b>Current liabilities :</b>		
Accounts payable	\$ 394,870	\$ 341,744
Accrued expenses	140,831	114,290
Loan from group companies	280,000	167,050
Current portion of operating lease	411	411
Current liabilities held-for-sale	256	424
<b>Total current liabilities</b>	<b>816,368</b>	<b>623,919</b>
<b>Long-term liabilities :</b>		
Operating lease - net of current portion	197	608
<b>Total current and long-term liabilities</b>	<b>816,565</b>	<b>624,527</b>
<b>Stockholders' equity</b>		
Common stock, \$1 per share par value - 3,000,000 shares authorized, issued and outstanding	3,000	3,000
Retained earnings	119,805	97,196
Treasury stock, at cost		
700,000 shares - March 31, 2024 and 2023	(28,000)	(28,000)
<b>Total stockholders' equity</b>	<b>94,805</b>	<b>72,196</b>
<b>TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</b>	<b>\$ 911,370</b>	<b>\$ 696,723</b>

-See accompanying notes to consolidated financial statements-

**ZYDUS PHARMACEUTICALS (USA) INC.**  
**Consolidated Statements of Income / (Operations)**  
**For the years ended March 31,**

*(all in thousands except shares)*

	<b>2024</b>	<b>2023</b>
<b>Net revenue</b>	\$ 946,810	\$ 853,182
Cost of sales	861,179	774,337
<b>Gross profit</b>	<b>85,631</b>	<b>78,845</b>
<b>Operating expenses:</b>		
General and administrative expenses	54,857	53,974
Total operating expenses	54,857	53,974
<b>Operating income before other income and (expense)</b>	<b>30,774</b>	<b>24,871</b>
<b>Other income and (expense):</b>		
Depreciation	(1,083)	(844)
Amortization	(29)	(20)
Interest income	6,703	2,403
Interest expense	(10,318)	(6,633)
<b>Total other income and (expense)</b>	<b>(4,727)</b>	<b>(5,093)</b>
<b>Income (loss) from continuing operations, before tax</b>	<b>26,047</b>	<b>19,778</b>
Income taxes:		
Federal income tax	(37,760)	(5,788)
State income tax	(1,522)	(426)
Deferred income tax	33,044	1,717
Income taxes	(6,238)	(4,497)
<b>Income (loss) from continuing operations</b>	<b>19,809</b>	<b>15,281</b>
<b>Discontinued operations (Note 3)</b>		
Profit / (Loss) from operations of discontinued activity	3,544	(1,406)
Income tax expense	(744)	295
<b>Income (loss) from discontinued operations</b>	<b>2,800</b>	<b>(1,111)</b>
<b>Net income (loss)</b>	<b>\$ 22,609</b>	<b>\$ 14,170</b>

-See accompanying notes to consolidated financial statements-

**ZYDUS PHARMACEUTICALS (USA) INC.**  
**Consolidated Statement of Changes in Stockholders' Equity**  
**For the years ended March 31, 2024 and 2023**

*(all in thousands except shares)*

	Common Stock		Retained earnings	Treasury stock		Total stockholders' equity
	Number of shares	Amount		Number of treasury stocks	Amount	
<b>Balance at March 31, 2022</b>	3,000,000	\$ 3,000	\$ 83,026	(700,000)	\$ (28,000)	\$ 58,026
Net income			14,170			14,170
<b>Balance at March 31, 2023</b>	3,000,000	\$ 3,000	\$ 97,196	(700,000)	\$ (28,000)	\$ 72,196
Net income			22,609			22,609
<b>Balance at March 31, 2024</b>	3,000,000	\$ 3,000	\$ 119,805	(700,000)	\$ (28,000)	\$ 94,805

-See accompanying notes to consolidated financial statements-

**ZYDUS PHARMACEUTICALS (USA) INC.**  
**Consolidated Statements of Cash Flows**  
**For the period ended March 31,**

*(all in thousands except shares)*

	<b>2024</b>	<b>2023</b>
<b>Cash flows from operating activities</b>		
Net income/(loss)	\$ 22,609	\$ 14,170
Less net income (loss) from discontinued operations	3,544	(1,406)
Net income from continuing operations	19,065	15,576
Adjustment to reconcile net income to net cash provided by (used in) operating activities		
Depreciation and amortization	1,112	864
Deferred income taxes	(33,044)	(1,717)
Changes in assets and liabilities :		
(Increase) / decrease in :		
Accounts receivable	(27,973)	(77,985)
Inventory	(84,842)	(2,723)
Prepaid expenses	(534)	271
Other current assets	(13,042)	(568)
Other assets	(56,872)	19,386
Increase / (decrease) in :		
Accounts payable	52,107	129,461
Accrued expenses	26,541	7,808
Net cash provided by (used in) operating activities - continuing operations	(117,482)	90,373
Net cash provided by (used in) operating activities - discontinued operations	(92)	1,782
<b>Cash flows from investing activities</b>		
Capital expenditures	(2,082)	(3,361)
Net cash provided by (used in) investing activities - continuing operations	(2,082)	(3,361)
Net cash provided by (used in) investing activities - discontinued operations	4,000	11,664
<b>Cash flows from financing activities</b>		
(Decrease) / Increase in line of credit	172	(75,000)
(Decrease) / Increase in loan from group companies	112,950	(2,950)
Net cash provided by (used in) investing activities - continuing operations	113,122	(77,950)
Net cash provided by (used in) investing activities - discontinued operations	(3,974)	(14,105)
<b>Net increase (decrease) in cash and cash equivalents</b>	(6,508)	8,402
<b>Cash and cash equivalent at the beginning of the year</b>	12,118	3,716
<b>Cash and cash equivalent at the end of the year</b>	<b>\$ 5,610</b>	<b>\$ 12,118</b>
<b>Supplementary disclosure of cash flows information:</b>		
<b>Cash paid during the years for:</b>		
Income taxes	\$ 17,664	\$ 3,762
Interest	10,318	6,731

-See accompanying notes to consolidated financial statements-

## ZYDUS PHARMACEUTICALS (USA), Inc.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the years ended March 31, 2024 and 2023  
(In thousands except share and per share data)

#### 1) Organization and Description of Business

Zydus Pharmaceuticals (USA) Inc (“the Company”) was incorporated in New Jersey on November 18, 2003 and is a 100% subsidiary of Zydus Lifesciences Limited, India, (“Zydus Life”).

The Company markets and distributes Generic and Authorized Generic pharmaceutical products in the United States of America. The Company also markets and distributes products manufactured by third parties.

The corporate office of the Company is located at Pennington, New Jersey. The building is owned by Zydus Healthcare (USA) LLC (“Zydus Healthcare”), a related party.

#### **Nesher Pharmaceuticals (USA) LLC**

Nesher Pharmaceuticals (USA) LLC (“Nesher”) which is a 100% subsidiary of the Company was formed in the State of Missouri on May 17, 2011.

Nesher has discontinued its operations from September 2021 and have been considered and disclosed as “Discontinued Operations” as per ASC 205-20. All the assets and liabilities related to these operations have been considered as "Held for sale" as per ASC 205-20 and disclosed separately in Balance Sheet. Refer note 3 “Discontinued Operations”.

#### **ZyVet Animal Health Inc.**

ZyVet Animal Health Inc (“ZyVet”) which is a 100% subsidiary of the Company was formed in the State of New Jersey on April 9, 2019 to market and distribute pharmaceutical products for animal consumption. ZyVet has started its commercial operations during the current year.

#### 2) Summary of Significant Accounting Policies

##### *Basis of consolidated financial statements*

The consolidated financial statements include the financial statements of the Company and its Subsidiaries. All significant related party accounts and transactions between the Company and the Subsidiaries have been eliminated upon consolidation. Previous year’s numbers are regrouped wherever necessary.

##### *Accounting Policies*

These financial statements are prepared on the accrual basis of accounting in conformity with accounting principles generally accepted in the United States of America (US GAAP); consequently, revenue is recognized when services are rendered, and expenses are reflected when costs are incurred.

## ZYDUS PHARMACEUTICALS (USA), Inc.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the years ended March 31, 2024 and 2023  
(In thousands except share and per share data)

#### *Use of Estimates*

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and use assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are often based on judgments, probabilities and assumptions that management believes are reasonable but that are inherently uncertain and unpredictable. As a result, actual result could differ from those estimates. Management periodically evaluates estimates used in the preparation of the consolidated financial statements for continued reasonableness. Appropriate adjustment, if any, to the estimates used are made prospectively based on such periodic evaluations.

#### *Revenue Recognition*

##### *General*

The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers.

A contract with a customer exists only when the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party's rights regarding the distinct goods or services to be transferred ("performance obligations"), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.

The amount of consideration to which the Company expects to be entitled varies as a result of rebates, chargebacks, returns and other sales reserves and allowances ("SR&A") that the Company offers to its customers and their customers, as well as the occurrence or nonoccurrence of future events, including milestone events. A minimum amount of variable consideration is recorded by the Company concurrently with the satisfaction of performance obligations to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Estimates of variable consideration are based on historical experience and the specific terms in the individual agreements (which the Company believes approximates expected value). Rebates and chargebacks are the largest components of SR&A. For further description of SR&A components and how they are estimated, see "Variable Consideration" below.

Shipping and handling costs are recorded under Selling and Marketing expenses.



## ZYDUS PHARMACEUTICALS (USA), Inc.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the years ended March 31, 2024 and 2023  
(In thousands except share and per share data)

#### *Nature of revenue streams*

Most of the Company's contracts related to product sales include single performance obligation, which is to deliver products to customers based on the purchase orders received. Revenue from sales of goods, including sales to distributors is recognized when the customer obtains control of the product. This generally occurs when products are shipped and delivered to the customer and the Company has determined that physical possession, legal title and risk and rewards of ownership of the products are transferred to the customer and Company is entitled to payment. The amount of consideration the Company expects to be entitled includes invoice value, net of accruals for estimated variable considerations including but not limited to wholesaler's chargeback, rebates, distribution service fees, returns and allowances, discount, incentives and other allowances.

Other revenues are primarily comprised of contract manufacturing services and other miscellaneous items. Revenue is recognized when the customer obtains control of the products. This generally occurs when products are shipped once the Company has a present right to payment and legal title and risk and rewards of ownership are obtained by the customer.

#### *Contract assets and liabilities*

Contract assets are mainly comprised of trade receivables net of allowance for doubtful debts, which includes amounts billed and currently due from customers.

Contract liabilities are mainly comprised of deferred revenues which were Nil as of March 31, 2024 and 2023.

#### *Variable consideration*

Variable consideration mainly includes SR&A, comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. All variable considerations except Medicaid and returns are netted against trade receivables. The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. The following describes the nature of each deduction and how provisions are estimated:

#### *Chargebacks*

The Company has agreements with certain indirect customers, such as independent pharmacies, retail pharmacy chains, managed care organizations, hospitals, governmental agencies and pharmacy benefit managers, which establish contract prices for certain products. The indirect customers then independently select a wholesaler from which to purchase the products at these contracted prices. Alternatively, certain wholesalers may enter into agreements with indirect customers that establish contract pricing for certain products, which the wholesalers provide. Under either arrangement, the Company will provide credit to the

## ZYDUS PHARMACEUTICALS (USA), Inc.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the years ended March 31, 2024 and 2023  
(In thousands except share and per share data)

wholesaler for any difference between the contracted price with the indirect party and the wholesaler's invoice price. Such credits are called chargebacks. The provision for chargebacks is based on expected sell-through levels by the wholesaler customers to indirect customers, as well as estimated wholesaler inventory levels at a given date.

#### *Rebates, promotional programs and other sales allowances*

This category includes rebate and other programs to assist in product sales. These programs generally provide that the customer receives credit directly related to the amount of purchases or credits upon the attainment of pre-established volumes. Also included in this category are prompt pay discounts, administrative fees and price adjustments to reflect decreases in the selling prices of products. Since these rebates and allowances are contractually agreed upon, they are estimated based on the specific terms in each agreement based on historical trends and expected sales. Externally obtained inventory levels are evaluated in relation to estimates made for rebates payable to indirect customers.

#### *Medicaid and Other Governmental Rebates*

Pharmaceutical manufacturers whose products are covered by Medicaid, Medicare and other Government programs are required to provide a rebate to each state as a percentage of their average manufacturer's price for the products dispensed. Many states have also implemented supplemental rebate programs that obligate manufacturers to pay rebates in excess of those required under federal law. The Company estimates these rebates based on historical trends of rebates paid, as well as on changes in wholesaler inventory levels and increases or decreases in sales.

#### *Shelf Stock Adjustments*

The custom in the pharmaceutical industry is generally to grant customers a shelf stock adjustment based on the customers' existing inventory contemporaneously with decreases in the market price of the related product. The most significant of these relate to products for which an exclusive or semi-exclusive period exists. Provisions for price reductions depend on future events, including price competition, new competitive launches and the level of customer inventories at the time of the price decline. The Company regularly monitors the competitive factors that influence the pricing of its products and customer inventory levels and adjust these estimates where appropriate.

#### *Returns*

Returns primarily relate to customer returns of expired products which, the customer has the right to return six months before and up to one year following the expiration date. Such returned products are destroyed, and credits and/or refunds are issued to the customer for the value of the returns. Accordingly, no returned assets are recorded in connection with those products. The returns provision is estimated by applying a historical return rate to the amounts

**ZYDUS PHARMACEUTICALS (USA), Inc.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**For the years ended March 31, 2024 and 2023**

**(In thousands except share and per share data)**

of revenue estimated to be subject to returns. Revenue subject to returns is estimated based on the lag time from time of sale to date of return. The estimated lag time is developed by analyzing historical experience. Additionally, the Company considers specific factors, such as estimated levels of inventory in the distribution channel, product dating and expiration, size and maturity of launch, entrance of new competitors, changes in formularies and any changes to customer terms, for determining the overall expected levels of returns.

Accounts receivable balances in the Company's consolidated financial statements are presented net of SR&A (Sales Related Allowances) estimates. SR&A balances in accounts receivable were \$ 238,898 and \$ 231,115 on March 31, 2024 and 2023, respectively. SR&A balances within accounts payable and accrued expenses were \$ 87,631 and \$93,221 on March 31, 2024 and 2023, respectively.

The movements in the SRA reserve balances during the years ended March 31, 2024 and 2023 are as follows:

Balance at the beginning of the year	\$	<b>324,336</b>	\$	<b>305,159</b>
Accrual to reduce gross sales to net sales		2,007,620		1,931,369
Payments and other		<u>(2,005,427)</u>		<u>(1,912,192)</u>
<b>Balance at the end of the year</b>	<b>\$</b>	<b><u>326,529</u></b>	<b>\$</b>	<b><u>324,336</u></b>

The SRA accruals recorded to reduce gross product sales to net product sales were as follows for the years ended March 31,

	<u>2024</u>	<u>2023</u>
Gross product sales	\$ 2,954,430	\$ 2,784,551
Accruals to reduce gross sales to net sales	<u>(2,007,620)</u>	<u>(1,931,369)</u>
<b>Net product sales</b>	<b><u>\$ 946,810</u></b>	<b><u>\$ 853,182</u></b>
<i>Percentage of SRA accruals to gross sales</i>	67 %	69 %

The decrease in SRA accruals was primarily due to decrease in retail sale as percentage of total sale and change in product mix during 2023-24.

***Concentrations***

Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents and trade accounts receivable. The Company maintains cash balances, which may exceed federally insured limits. The Company does not believe that this results in any significant credit risk. As of March 31, 2024 and 2023, the Company had

## ZYDUS PHARMACEUTICALS (USA), Inc.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the years ended March 31, 2024 and 2023  
(In thousands except share and per share data)

\$4,326 and \$13,319, respectively, of uninsured cash balances.

Concentration of credit risks with respect to accounts receivable is limited because of the credit worthiness of the Company's major customers. The majority of the Company's accounts receivable arise from product sales in the United States and are primarily due from drug wholesalers and retailers, distributors and pharmacy benefit managers. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. Revenue from the Company's three major customers represented approximately 60% and 66% of the Company's net revenue for the years ended March 31, 2024 and 2023, respectively. Accounts receivable from the top three customers represented approximately 64% and 64% of total accounts receivable as of March 31, 2024 and 2023, respectively.

#### *Cash and cash equivalents*

The Company considers all highly-liquid investments (including money market funds) with an original maturity at acquisition of three months or less to be cash equivalents. The Company maintains cash balances, which may exceed federally insured limits. The Company does not believe that this results in any significant credit risk.

#### *Accounts receivable*

The Company extends credit to clients based upon management's assessment of their creditworthiness on an unsecured basis. Accounts receivables are presented net of allowance for credit losses in the balance sheet.

#### *Allowance for Credit Losses*

The Entity adopted ASC 326, Financial Instruments--Credit Losses, as of April 1, 2023, with the cumulative-effect transition method with the required prospective approach. The measurement of expected credit losses under the current expected credit loss ("CECL") methodology is applicable to financial assets measured at amortized cost, which include accounts receivable and other contract assets. An allowance for credit losses under the CECL methodology is determined using the loss-rate approach and measured on a collective (pool) basis when similar risk characteristics exist. Where financial instruments do not share risk characteristics, they are evaluated on an individual basis. The CECL allowance is based on relevant available information, from internal and external sources, relating to past events, current conditions, and reasonable and supportable forecasts. The allowance for credit losses as of March 31, 2024, and change in the allowance for credit losses during the year ended March 31, 2024, was not material to the financial statements.

Prior to adoption of ASC 326, the Company maintained an allowance for doubtful accounts to reserve for potentially uncollectible receivables. The allowance for doubtful accounts as of March 31, 2023, was not material to the financial statements.

## ZYDUS PHARMACEUTICALS (USA), Inc.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the years ended March 31, 2024 and 2023  
(In thousands except share and per share data)

#### *Inventories*

Inventories are stated at the lower of cost or net realizable value. Cost is determined on a moving weighted average basis. The Company establishes reserves for its inventory to reflect situations in which the cost of the inventory is not expected to be recovered. In evaluating whether inventory is stated at the lower of cost or net realizable value, management considers such factors as the amount of inventory on hand; estimated time required to sell such inventory, remaining shelf life and current and expected market conditions, including level of competition. As of March 31, 2024 and 2023, provisions for the inventory reserves were \$39,099 and \$26,891, respectively.

#### *Property and Equipment*

Property and equipment are stated at cost less accumulated depreciation and impairment loss if any. The Company provides for depreciation of property and equipment using the straight-line method over the estimated useful lives of the related assets ranging from 3 to 39.5 years. The Company charges repairs and maintenance costs that do not extend the lives of the assets to expenses as incurred. Repairs and maintenance expenses during the years ended March 31, 2024 and 2023 were \$518 and \$210, respectively.

#### *Intangible assets*

The Company amortize intangible assets with finite lives on a straight-line basis over their estimated useful lives. Intangible assets are reviewed annually for impairment or when events or circumstances indicate their carrying amount may not be recoverable. Based on the evaluation of intangible assets completed during the years ended March 31, 2024 and 2023, no impairment was recorded.

#### *Impairments*

In accordance with U.S. GAAP, we evaluate the carrying amount of our long-lived assets such as property and equipment, and finite-lived intangible assets subject to amortization for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets held and used is measured by the comparison of its carrying amount with the future net cash flows the asset is expected to generate. We look primarily to the undiscounted future cash flows in the assessment of whether or not long-lived assets have been impaired. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the estimated fair value of the asset. The Company has recorded impairment gain of \$ 3,511 and \$ Nil respectively for the years ended March 31, 2024 and 2023 for its manufacturing facilities located in St. Louis Missouri.

## ZYDUS PHARMACEUTICALS (USA), Inc.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the years ended March 31, 2024 and 2023  
(In thousands except share and per share data)

#### *Discontinued Operations.*

ASC 205-20-45, "Presentation of Financial Statements Discontinued Operations" requires discontinued operations to be reported if the disposal of a business component represents a strategic shift that has a major effect on an entity's operations and financial reports. It is determined that the sale of the assets and discontinuation of business operations of Nesher Pharmaceuticals (USA) LLC meet this criterion. Accordingly, the assets, liabilities, revenues, and income statement of these entities were transferred to discontinued operations to close out the business. See Note 3 "Discontinued Operations", for additional disclosures regarding this entity.

#### *Fair Value Measurements*

FASB ASC 820, *Fair Value Measurements and Disclosures* defines fair value and establishes a hierarchy for reporting the reliability of input measurements used to assess fair value for all assets and liabilities. FASB ASC 820 defines fair value as the selling price that would be received for an asset, or paid to transfer a liability, in the principal or most advantageous market on the measurement date. That framework provides a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurements). The asset or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. Certain financial instruments are carried at cost on the balance sheet, which approximates fair value due to their short-term, highly liquid nature. These instruments include cash, accounts receivable, accounts payable and accrued expenses and other liabilities.

#### *Income taxes*

Income taxes have been provided for using an assets and liability approach in which deferred tax assets and liabilities are recognized for the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is provided for the portion of deferred tax assets when, based on available evidence, it is not "more-likely-than-not" that a portion of the deferred tax assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rate and laws.

The Company's effective tax rate is 24% for period ended March 31, 2024 and 23% for the period ended March 31, 2023. The future effective income tax rate depends on various factors, such as the Company's income (loss) before taxes, tax legislation and the geographic composition of pre-tax income.

## ZYDUS PHARMACEUTICALS (USA), Inc.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the years ended March 31, 2024 and 2023

(In thousands except share and per share data)

#### *Advertising expenses*

The Company expenses advertising as incurred. Advertising paid in advance is recorded as a prepaid expense until such time as the advertisement is published.

#### *Reclassifications*

Certain accounts in the prior-year financial statements have been reclassified for comparative purposes to conform with the presentation in the current-year financial statements.

### 3) Discontinued Operations

Nesher a Missouri based entity, manufactured five products including a product on contract basis until September 2021. The operations at Missouri facility was discontinued effective from September 2021. Nesher's both manufacturing facilities in St. Louis, Missouri were sold on April 6<sup>th</sup>, 2022. The vacant land adjacent to the manufacturing facility was sold on June 29<sup>th</sup>, 2022. The remaining building situated in St. Louis, Missouri is held for sale and hence all the assets and liabilities related to Nesher have been considered as "Held for sale" as per ASC 205-20 and disclosed separately in Balance Sheet.

The major classes of assets and liabilities of the entity classified as held for sale were as follows on March 31, 2024:

<i>Major classes of Assets</i>	
Current assets	\$ 151
Discontinued operations - current assets	151
Other assets	-
Total major classes of assets - discontinued operations	<u>\$ 151</u>
 <i>Major classes of Liabilities</i>	
Accounts payable	\$ -
Other liabilities	256
Total major classes of liabilities -discontinued operations	<u>\$ 256</u>

The financial results of the discontinued operations are as follows:

Revenue	\$ 595
Total operating costs and expenses	562
Income (loss) from discontinued operations	33
Other income (expense), net	3,511
Income tax benefit (expense)	-
Net income (loss) from discontinued operations	<u>\$ 3,544</u>

**ZYDUS PHARMACEUTICALS (USA), Inc.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**For the years ended March 31, 2024 and 2023**

**(In thousands except share and per share data)**

During the current year, Neshor sold the lab building. The total gross value of the assets sold were \$8,689 with accumulated depreciation totaling \$4,249. The sale value of all the assets sold was \$4,000 which resulted in a net loss of \$440. The corresponding impairment provision of \$3,951 made related to these assets were reversed in this year. The Company owns no more assets in St. Louis Missouri.

**4) Property and Equipment**

Consolidated property and equipment consisted of the following on March 31,

	2024	2023
Computer and Equipment	\$ 547	\$ 510
Furniture and Fixtures	1,412	1,409
Computer Software	8,523	7,048
Office Equipment	70	69
Leasehold Improvements	2,638	2,123
Fixed Assets in progress	638	613
	13,828	11,772
Less: Accumulated Depreciation	6,348	5,263
Net Fixed Assets	\$ 7,480	\$ 6,509

Depreciation expenses during the years ended March 31, 2024 and 2023 were \$1,083 and \$844 respectively.

**5) Intangible assets**

Intangible assets consisted of the following at March 31,

	2024	2023
Logo	\$ 211	\$ 179
Accumulated amortization	(99)	(71)
Total	\$ 112	\$ 108

Amortization expense during the years ended March 31, 2024 and 2023 were \$29 and \$ 20. Estimated amortization expenses for intangible assets for each of the next five years are as follows:



**ZYDUS PHARMACEUTICALS (USA), Inc.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**For the years ended March 31, 2024 and 2023**

**(In thousands except share and per share data)**

Period ending March 31,		
2025	\$	29
2026		29
2027		29
Thereafter,		25
Total	\$	112

**6) Other assets**

Other current assets represent the amount that was paid in advance towards federal and state taxes. The balance in other assets includes loan and advances to Zydus Healthcare (USA) LLC., Zydus Noveltech Inc., Sentyln Therapeutics Inc., Zydus Therapeutics Inc. and Viona Pharmaceuticals Inc., which are related parties. The Company charges interest at arm’s length rates on these loans given to related parties. Loan and advances outstanding were as follows for the years ended March 31,

	2024	2023
Zydus Healthcare (USA) LLC.	\$ 2,500	\$ 2,500
Sentyln Therapeutics Inc.	75,000	48,000
Zydus Therapeutics Inc.	57,237	26,100
Viona Pharmaceuticals Inc.	8,959	6,250
Total	\$ 143,696	\$ 82,850

**7) Accrued expenses**

Accrued expenses represent amounts accrued towards various expenses outstanding at the end of year. It also includes \$ 87,631 and \$ 93,221 respectively, for the years ended March 31, 2024 and 2023 towards Medicaid, Medicare, Tricare, Brand prescription fees, Product Returns, etc. accrued for different state and federal programs.

**8) Short-Term Debt**

*i) Loan from Zydus Lifesciences Limited.*

The Company had entered in to short-term loan agreement for \$170,000 with the parent company Zydus Lifesciences Limited. For the years ended March 31, 2024 and 2023 the outstanding loan amount was \$165,000 and \$ 165,000 respectively. The Company has paid interest at the applicable arm’s length rate.

*ii) Loan from Zydus Noveltech Inc.*

The Company had entered in to short-term loan agreement with the related company Zydus Noveltech Inc. For the years ended March 31, 2024 and 2023, the outstanding loan amount was

## ZYDUS PHARMACEUTICALS (USA), Inc.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the years ended March 31, 2024 and 2023

(In thousands except share and per share data)

\$ NIL and \$ 2,050 respectively. The Company has paid interest at the applicable arm's length rate.

*iii) Loan from Zydus International Private Limited.*

The Company had entered in to short-term loan agreement for \$115,000 with the related company Zydus International Private Limited. For the years ended March 31, 2024 and 2023 the outstanding loan amount was \$115,000 and \$ NIL respectively. The Company has paid interest at the applicable arm's length rate.

#### 9) Employee Benefit Plan

The Company participates in a savings plan under section 401(k) of the Internal Revenue Code (Code) covering all eligible employees. The plan provides that the Company can make matching contributions, which is equivalent to the employee's contributions subject to a maximum of 5% of the gross pay of the employee subject to Federal limits. All qualifying matching contributions are 100% vested at the completion of five years of service by an employee and are subject to certain withdrawal restrictions. For the years ended March 31, 2024 and 2023, the Company's contribution to the plan, were \$ 649 and \$ 588 respectively.

The Company has a deferred compensation plan in which certain key employees are eligible to participate. The plan allows each participant to accrue deferred compensation equal to their share, as further defined in the plan agreement, of annual net revenue growth measured against previous year annual net revenue. For example, the computation of deferred compensation for the year 2023 is based on the growth in annual net revenue for 2023 compared with 2022. The deferred liability for each participant vests equally over five-year period and vested amount is paid out at the end of the following year. The participant must be employed at the Company in order to be eligible for vesting and subsequent payment. If the participants employment is terminated any unvested amounts are forfeited. The Company may have an exception to this rule at its sole discretion. The Company accounts for the deferred compensation asset separately from the liability.

Deferred compensation payment for each of the next five years are expected to be as follows:

Period ending March 31,

2025	\$	1068
2026		914
2027		711
2028		711
2029		540
<b>Total</b>	<b>\$</b>	<b>3,944</b>

**ZYDUS PHARMACEUTICALS (USA), Inc.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**For the years ended March 31, 2024 and 2023**

**(In thousands except share and per share data)**

**10) Segment Information**

The Company has two reportable segment which are Human Health and Animal Health. Relevant information regarding both segments are as under. The Company has one Geographical segment which is Unites Sates of America.

<b>Particulars</b>	<b>March 31,</b>	
	<b>2024</b>	<b>2023</b>
<b>Segment Revenue</b>		
Human Health	\$ 936,741	\$ 853,182
Animal Health	10,069	-
Total revenue from continuing operations	\$ 946,810	\$ 853,182
<b>Segment Results</b>		
Human Health	\$ 25,963	\$ 20,906
Animal Health	84	(1,128)
Total profit before tax	\$ 26,047	\$ 19,778
<b>Segment Assets</b>		
Human Health	\$ 905,451	\$ 695,327
Animal Health	5,919	1,396
Total Assets	\$ 911,370	\$ 696,723
<b>Segment Liabilities</b>		
Human Health	\$ 808,032	\$ 620,432
Animal Health	8,535	4,095
Total Liabilities	\$ 816,567	\$ 624,527

**11) Related Party Transactions**

**Name of the Related Parties and the Nature of the Relationship:**

**a. Related entities**

Zydus Lifesciences Limited	Zydus Worldwide DMCC
Zydus International Private Limited	Hercon Pharmaceuticals (USA) LLC
Zydus Noveltech Inc	Zydus Animal Health and Investments Limited
Sentynl Therapeutics Inc	Zydus Lifesciences Global FZE
Viona Pharmaceuticals Inc	Zydus Pharmaceuticals (Canada) Inc
Zydus Healthcare (USA) LLC	Zynext Ventures USA LLC
Zydus Therapeutics Inc	

**ZYDUS PHARMACEUTICALS (USA), Inc.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**For the years ended March 31, 2024 and 2023**

**(In thousands except share and per share data)**

**b. Enterprises significantly influenced by Directors and/or their relatives with whom transactions have taken place:**

NAI Laboratories Limited

Navinta III, Inc

Navinta LLC

Navinta NV, Inc

Mahadev Management Inc

The following transactions were carried out with the related parties in the ordinary course of business for the year ended March 31,

<b>Nature of Transactions</b>	<b>2024</b>	<b>2023</b>
<b>Purchases:</b>		
<b>Goods</b>		
Zydus Lifesciences Limited	\$ 774,566	\$ 661,140
Zydus Worldwide DMCC	120,171	67,811
Zydus Animal Health and Investments Limited	10,804	-
Navinta NV, Inc	8,916	9,344
Navinta LLC	2,267	2,930
Navinta III, Inc	1,210	686
NAI Laboratories Limited	1,209	1,075
Zydus Lifesciences Global FZE	46	-
Total	<u>\$ 919,189</u>	<u>\$ 742,986</u>
<b>Material</b>		
Zydus Lifesciences Limited	\$ -	\$ 37
Total	<u>\$ -</u>	<u>\$ 37</u>
<b>Lease</b>		
Zydus Healthcare (USA) LLC	\$ 440	\$ 434
Total	<u>\$ 440</u>	<u>\$ 434</u>
<b>Management Consultancy Services</b>		
Mahadev Management Inc	\$ 673	\$ 230
Total	<u>\$ 673</u>	<u>\$ 230</u>
<b>Reimbursement of Net Expenses Paid</b>		
Navinta LLC	\$ 183	\$ 187
Total	<u>\$ 183</u>	<u>\$ 187</u>

**ZYDUS PHARMACEUTICALS (USA), Inc.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**For the years ended March 31, 2024 and 2023**

**(In thousands except share and per share data)**

**Services**

Zydus Lifesciences Limited	\$ 498	\$ 661
Total	<u>\$ 498</u>	<u>\$ 661</u>

**Sales:**

**Reimbursement of Net Expenses Recovered**

Zydus Lifesciences Limited	\$ 7,319	\$ 27,445
Zydus Worldwide DMCC	6,103	3,125
Zydus Animal Health and Investments Limited	1,598	-
Viona Pharmaceuticals Inc	137	116
Sentynl Therapeutics Inc	93	62
Zydus Healthcare (USA) LLC	42	50
Zydus Lifesciences Global FZE	28	-
Zynext Ventures USA LLC	12	1
Zydus Therapeutics Inc	11	6
Zydus Pharmaceuticals (Canada) Inc	2	-
Navinta NV, Inc	-	8
Hercon Pharmaceuticals (USA) LLC	-	341
Total	<u>\$ 15,345</u>	<u>\$ 31,154</u>

**Finance:**

**Interest Expense**

Zydus Lifesciences Limited	\$ 9,769	\$ 5,322
Zydus Noveltech Inc	87	43
Zydus International Private Limited	64	-
Total	<u>\$ 9,920</u>	<u>\$ 5,365</u>

**Interest Income**

Sentynl Therapeutics Inc	\$ 3,448	\$ 1,491
Zydus Therapeutics Inc	2,337	606
Viona Pharmaceuticals Inc	399	182
Zydus Healthcare (USA) LLC	150	139
Zydus Noveltech Inc	-	18
Total	<u>\$ 6,334</u>	<u>\$ 2,436</u>

**Outstanding:**

**Payable: Loans**

Zydus Lifesciences Limited	\$ 165,000	\$ 165,000
Zydus Noveltech Inc	-	2,050
Zydus International Private Limited	115,000	-
Total	<u>\$ 280,000</u>	<u>\$ 167,050</u>

**ZYDUS PHARMACEUTICALS (USA), Inc.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**For the years ended March 31, 2024 and 2023**

**(In thousands except share and per share data)**

**Payable: Other than loans**

Zydus Lifesciences Limited	\$ 393,844	\$ 287,135
Navinta NV, Inc	1,037	2,454
NAI Laboratories Limited	587	156
Navinta LLC	427	281
Zydus International Private Limited	64	-
Navinta III, Inc	41	60
Zydus Lifesciences Global FZE	18	-
Zydus Noveltech Inc	-	26
Zydus Worldwide DMCC	-	40,486
<b>Total</b>	<b>\$ 396,018</b>	<b>\$ 330,598</b>

**Receivable: Loan**

Sentynl Therapeutics Inc	\$ 75,000	\$ 48,000
Zydus Therapeutics Inc	57,237	26,100
Viona Pharmaceuticals Inc	8,959	6,250
Zydus Healthcare (USA) LLC	2,500	2,500
<b>Total</b>	<b>\$ 143,696</b>	<b>\$ 82,850</b>

**Receivable: Other than loans**

Zydus Worldwide DMCC	\$ 10,338	\$ -
Sentynl Therapeutics Inc	1,060	567
Zydus Therapeutics Inc	503	106
Viona Pharmaceuticals Inc	95	92
Zynext Ventures USA LLC	14	-
Zydus Pharmaceuticals (Canada) Inc	2	-
Zydus Healthcare (USA) LLC	1	-
Hercon Pharmaceuticals (USA) LLC	-	62
Zydus Animal Health and Investments Limited	-	101
<b>Total</b>	<b>\$ 12,013</b>	<b>\$ 928</b>

**12) Product Liability**

Accruals for product liability claims if any are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information. The accruals are adjusted periodically as additional information becomes available. From time to time the Company is subject to claims and law suits arising in the ordinary course of business, including patent, product liability and other litigation. In determining whether liabilities should be recorded for pending claims, the Company assesses the allegations made and the likelihood that it will be able to defend against the claim successfully. The Company records provisions to the extent it concludes that a contingent liability is probable, and the amount thereof is estimable. Because litigation outcomes and contingencies are unpredictable, and because excessive verdicts can occur, these

## ZYDUS PHARMACEUTICALS (USA), Inc.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the years ended March 31, 2024 and 2023

(In thousands except share and per share data)

assessments involve complex judgments about future events and can rely heavily on estimates and assumptions. The Company is involved in product liability lawsuits related to alleged personal injuries arising out of use of product distributed by the Company. The Company believes that it has meritorious defenses to the lawsuit and is vigorously defending itself with respect to this matter. For the years ended March 31, 2024 and 2023, no accruals for product liability were made. Zydus Life, the parent Company reimburses product liability related expenses incurred by the Company in case of any claims on products sourced from them.

#### 13) Contingent Liability

The Company has guaranteed a severance package covering three to six months of annual salary to some of its employees for the years 2024 and 2023, in the event the Company terminates employment for reason other than cause and in case of voluntary termination of employment due to significant and adverse change to; title, current salary, mandatory relocation or change in management reporting structure. The contingent liabilities for the years ended March 31, 2024 and 2023 were approximately \$ 3,387 and \$ 2,288, respectively.

#### 14) Legal Settlements and Proceedings

The Company is involved in, or has been involved in, legal proceedings that arise from the normal course of business. The Company cannot predict the timing or outcome of these claims and other proceedings. Currently, the Company is not involved in any arbitration and/or other legal proceedings that it expects to have a material effect on the business, financial condition, results of operations or liquidity of the Company. All legal cost is expensed as incurred.

#### *Government Investigations and Litigation Relating to Generic Products Pricing*

In late 2016, a union health and welfare fund filed two actions against the Company and other generic drug companies in the U.S. District Court for the Eastern District of Pennsylvania. These actions alleged conspiracies to fix prices or allocate markets for two drugs (divalproex and pravastatin) in violation of federal and state antitrust laws. Subsequently, these and the other actions detailed below have been coordinated in a multi-district litigation in the Eastern District of Pennsylvania. Ultimately, putative classes of direct purchasers, end payors, and indirect resellers each filed multiple actions in which the Company is named as one of several defendants: (i) an action alleging a conspiracy to fix prices or allocate markets for pravastatin, (ii) an action to fix prices or allocate markets for divalproex, and (iii) an action alleging both a conspiracy to fix prices or allocate markets for a third drug (acetazolamide) as well as an “overarching,” industry-wide conspiracy. In June 2018, Connecticut and other states filed a complaint against the Company and other defendants alleging a number of individual-drug conspiracies (including acetazolamide for the Company) as well as an “overarching” conspiracy. Several opt-out plaintiffs have filed complaint as well, and the claims in these complaints track the claims outlined above. In May 2019, Connecticut and other states filed a second complaint against the Company and other defendants. That complaint alleges a

## ZYDUS PHARMACEUTICALS (USA), Inc.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the years ended March 31, 2024 and 2023

(In thousands except share and per share data)

number of individual-drug conspiracies (including eight drugs for the Company) as well as an “overarching” conspiracy. Beginning in October 2019, putative classes of direct purchases, indirect resellers, and end payors as well as several opt-out plaintiffs and a group of New York counties filed additional complaints against the Company and other defendants with substantially similar claims. In October 2019, the Court entered a case management order setting a preliminary schedule and the cases are currently proceeding through fact discovery. No trial dates have been set for the Company. The Company believes it has meritorious defenses to these lawsuits.

#### *Government Investigations and Litigation Relating to Opioids*

In late 2019 four cases were filed against Zydus in an existing MDL in Ohio. In April 2023, 3 additional cases were filed in the Ohio MDL. In April 2023, 35 cases were filed in a New York Coordinated proceedings. The cases are similar, generally alleging that Zydus manufactured, marketed and sold opioids and failed to effectively and adequately communicate warnings and risks of opioids use to both prescribers and users. The cases also generally allege Zydus failed to report suspicious orders. The lawsuits are seeking relief under several theories, including a theory of public nuisance. The Company believes it has meritorious defenses to these lawsuits.

#### **15) Income Tax**

The Company accounts for income taxes in accordance with FASB ASC Topic 740, *Income Taxes*. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Management evaluates all available evidence about future taxable income and other possible sources of realization of deferred tax assets. A valuation allowance is established to reduce deferred tax assets to an amount that represents management’s best estimate of the amount of such deferred tax assets that more likely than not will be realized. To the extent the Company establishes a valuation allowance or increased the allowance in any given period, an expense is recognized within the provision for income taxes in the statement of income.

The Company recognizes the tax benefit from uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefit is measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement. The Company recognizes interest and penalties related to income tax matters as other expense in the statement of income. Based on management’s evaluations, there are no uncertain tax positions requiring recognition as of the date of these financial statements.

Income tax expense (benefit) was computed as follows for the years ended March 31,



**ZYDUS PHARMACEUTICALS (USA), Inc.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**For the years ended March 31, 2024 and 2023**  
**(In thousands except share and per share data)**

	2024	2023
Federal income tax	\$ 38,504	\$ 5,493
State income tax	1,522	426
Total income taxes, current provision	40,026	5,919
Deferred income taxes (benefit)	(33,044)	(1,717)
Total income tax expense (benefit)	\$ 6,982	\$ 4,202

The deferred tax assets (liabilities) consist of the following at March 31,

	2024	2023
Property and equipment	\$ (1,180)	\$ (203)
Sales accruals and other items	64,704	30,683
Total deferred income taxes	\$ 63,524	\$ 30,480

In view of the release of regulations by the IRS and Treasury for final regulations (T.D. 9941) addressing the timing of income recognition for accrual-method taxpayers under Secs. 451(b) and 451(c), and amendments to it by the 2017 law known as the Tax Cuts and Jobs Act (TCJA), P.L. 115-97 requires the Company to change its method of income tax calculation for chargebacks to align with the final regulations. The new method will conform with the recurring item exception provided under IRC section 461(h)(3) and corresponding regulations 1.461-5. As a consequence of the new regulations, the Company has created a deferred tax asset of \$31,691 in the financial statements reported for the year ending March 31, 2024.

The Company's provision for income taxes differs from applying the statutory U.S. federal income tax rate to income before income taxes. The primary differences result from different State income tax effective rates that were used in the accrual for the income provision for financial statement purposes versus the actual rate realized on the income tax returns. The Company files its income tax returns on a calendar year basis.

The Company files income tax returns in the U.S. federal jurisdiction, and various State jurisdictions. The Company is generally no longer subject to U.S. Federal, State and local examinations by tax authorities for the years before 2020. There are no on-going open period income tax audits with any Federal, State and/or local tax authorities.

**16) Supply and Distribution Agreement**

The Company has entered into a supply and distribution agreement with Zydus Life, its parent Company. Zydus Life has appointed the Company as its exclusive distributor in US territory to

## ZYDUS PHARMACEUTICALS (USA), Inc.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the years ended March 31, 2024 and 2023

(In thousands except share and per share data)

sell, warehouse and distribute the products, either directly or through its sub-distributors. The agreement also records the entire understanding between the parties in respect of development, approvals (regulatory), manufacture, quality control, and liabilities of the parties in respect of claims from third parties and or as between the parties for pre-manufacturing and post-manufacturing defects and operations. The agreement also sets the parameter for determining the price, which shall be reviewed periodically, to enable the Company to earn return on an arm's length basis for the distribution functions that it performs, having regard to its assets utilized, and risks undertaken.

#### 17) New Accounting Pronouncements

i) Accounting Standards Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (Credit Losses) - The amendment in this ASU affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in this update affect an entity to varying degrees depending on the credit quality of the assets held by the entity, their duration, and how the entity applies current GAAP. Accounting Standards Update 2019-10 amends the mandatory effective dates for implementation of accounting for Credit Losses for all entities as follows:

Public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early application continues to be allowed. The Company adopted ASU 2016-02 effective from April 1, 2023. The adoption of ASU 2016-02 standard did not have a material impact on the Company's financial statements.

#### 18) Leasing Arrangements

The Company leases certain office space. The Company assesses whether an arrangement qualifies as a lease (i.e., conveys the right to control the use of an identified asset for a period of time in exchange for consideration) at inception and only reassesses its determination if the terms and conditions of the arrangement are changed. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense is recognized for these leases on a straight-line basis over the lease term.

The lease terms include options to extend the leases when it is reasonably certain that the Company will exercise that option. These operating leases contain renewal options for periods ranging from three to five years that expire at various dates with no residual value guarantees. Future obligations relating to the exercise of renewal options is included in the measurement if,

**ZYDUS PHARMACEUTICALS (USA), Inc.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**For the years ended March 31, 2024 and 2023**

**(In thousands except share and per share data)**

based on the judgment of management, the renewal option is reasonably certain to be exercised. Factors in determining whether an option is reasonably certain of exercise include, but are not limited to, the value of leasehold improvements, the value of the renewal rate compared to market rates, and the presence of factors that would cause a significant economic penalty to the Company if the option is not exercised. The exercise of lease renewal options is at the Company's sole discretion. Certain leases also include options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited by the expected lease term unless there is a transfer of title or purchase option reasonably certain of exercise.

The lease assets and liabilities were calculated utilizing the risk-free discount rate (3.60%), according to the Company's elected policy.

	Classification	03/31/2024
<b>Assets</b>	Operating lease right of use assets	\$ 600
<b>Liabilities</b>	Current portion of operating lease	\$ 411
	Noncurrent portion of operating lease	\$ 197

Operating lease costs for the years ended March 31, 2024 and 2023, was \$434 and \$426 and is included in selling, general and administrative expenses in the accompanying statement of income.

Supplemental cash flow and other information is as follows:

Cash paid for amounts included in the measurement of lease liabilities:

Operating cash flows from operating leases	\$	440
Lease assets obtained in exchange for lease liabilities		1,365
Weighted-average remaining lease term (years)		1.42
Weighted average discount rate		3.60%

Total future minimum payments required under the lease obligations are as follows as of March 31, 2024,

	2025	\$ 440
	2026	182
Total lease payments		622
Less: amount representing interest		14
Total lease obligation		\$ 608

**ZYDUS PHARMACEUTICALS (USA), Inc.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**For the years ended March 31, 2024 and 2023  
(In thousands except share and per share data)**

**19) Contingencies**

The Company is involved in product liabilities, government investigation and other legal proceedings that arise from time to time in the ordinary course of business. The Company records accruals for these types of contingencies to the extent that the Company determines their occurrence is probable and that the related liabilities are estimable. When accruing these costs, the Company will recognize an accrual of best estimable amount based on the data and knowledge available.

**20) Subsequent events**

The Company has evaluated subsequent events through May 15, 2024, the date, which the financial statements were available to be issued. No reportable subsequent events have occurred through May 15, 2024, which would have a significant effect on the financial statements as of March 31, 2024, except as otherwise disclosed.